A practical reference on 三重激动剂: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
==== Innate immune system ==== There are many regulators which affect immune system and help to keep it balanced. If the immune system is too active there is a danger of developing an autoimmune disease, while passive immune system will lead to infections or cancer. Antigen presenting is a key role in activation of immune system. It has been discovered that AEP plays role in this critical moment. AEP is involved in presenting of foreign and self proteins using MHCII protein complex. The role of AEP in immunity is not clear, but it seems that it is connected with checkpoint inhibitors such as PD-1, which downregulates AEP which is key to shifting the balance between cancer fighting cells and regulatory T cells. In the absence of AEP, inhibitory checkpoints may not have a beneficial response. Measuring of this enzyme in patients could predict which one of them may provide better response to treatment.
=== Internal standards === Sometimes an internal standard is added at a known concentration directly to an analytical sample to aid in quantitation. The amount of analyte present is then determined relative to the internal standard as a calibrant. An ideal internal standard is an isotopically enriched analyte which gives rise to the method of isotope dilution.
As a result of these differences in molecular weights, EMP contains about 52%, EMP sodium about 48%, and EMP meglumine about 38% of the amount of estradiol within their structures as does an equal-mass quantity of estradiol.
Ribosomes from bacteria, archaea, and eukaryotes (in the three-domain system) resemble each other to a remarkable degree, evidence of a common origin. They differ in their size, sequence, structure, and the ratio of protein to RNA. The differences in structure allow some antibiotics to kill bacteria by inhibiting their ribosomes while leaving human ribosomes unaffected. In all domains, a polysome of two or more ribosomes may move along a single mRNA chain at one time, each reading a specific sequence and producing a corresponding protein molecule. The mitochondrial ribosomes (mitoribosomes) of eukaryotic cells are distinct from the other ribosomes. They functionally resemble those in bacteria, reflecting the evolutionary origin of mitochondria as endosymbiotic bacteria.
The seventh generation Familia (BG) included three-door hatchback, five-door liftback, and four-door saloon variants, none of which share any body panels. The new five-door liftback version was called the Familia Astina in Japan and was sold as the 323F or 323 Astina elsewhere. The BF wagon (originally introduced in 1985) was carried over in facelifted form, although Ford marketed a wagon on the new platform as part of the North American Escort line. The BG Familia was available with front- or all-wheel drive and 1.3–1.8 L petrol engines or a 1.7 L diesel engine. Later, a turbocharged engine was added, especially developed for homologation purposes for the World Rally Championship (WRC), Group A category. The all-wheel drive models (including the turbocharged GT-X) were introduced in August 1989. In Japan, the 1.6 L SOHC was only available coupled to all-wheel drive. With a carburettor, it offered 91 PS (67 kW; 90 hp), the same as the lower-spec 1.5 L SOHC, but with a somewhat larger torque curve. In Europe, only the 1.8 L SOHC (in naturally aspirated, 106 PS (78 kW; 105 hp) form or either of the turbocharged variants) was offered with four-wheel-drive. Trim lines in Japan included "Clair", "Pepper", "Interplay", "Supreme", "GT", "GT-X" and "GT-R". The Supreme model was only available in saloon form and features the larger bumpers and bootlid-mounted number plate recess of the American market Protegé. Carburetted models were mostly dropped in the 1991 facelift, replaced by single-point fuel injection.
Sources: en.wikipedia.org
In contrast to other mechanical disruption methods the Microfluidizer breaks the cell membranes efficiently but gently, resulting in relatively large cell wall fragments (450 nm), and thus making it easier to separate the cell contents. This can lead to shorter filtration times and better centrifugation separation. Microfluidizer technology scales from one milliliter to thousands of liters.
==== Absorption ==== When taken orally, DMT is metabolized by monoamine oxidase (MAO) enzymes in the liver and gut, and is thus not orally bioavailable unless a monoamine oxidase inhibitor (MAOI) is taken (as is naturally found in the ayahuasca brew). As such, DMT by itself is instead taken by parenteral administration. Closely coextending with peak psychedelic effects, the mean time to reach peak concentration (Tmax) has been determined to be 10 to 15 minutes in whole blood after intramuscular injection, and 2 to 3 minutes after intravenous administration. When taken orally mixed in an ayahuasca decoction or in freeze-dried ayahuasca gel caps, DMT Tmax is considerably delayed to 1.8 hours on average, and 1.5 to 2 hours, respectively. DMT peak level concentrations (Cmax) measured in the blood after intramuscular (IM) injection (0.7 mg/kg, n = 11) and in plasma following intravenous administration (0.4 mg/kg, n = 10) of fully psychedelic doses are in the range of around 14 to 154 μg/L and 32 to 204 μg/L, respectively. The corresponding molar concentrations of DMT are therefore in the range of 0.074–0.818 μmol/L in whole blood and 0.170–1.08 μmol in plasma.
Narrated by Fisher Dilke, produced by Nick Catliff, made by Lion Television 10 May A Sense of Disaster, about predicting earthquakes; Allan Lindh of the USGS; 17 October 1989 a large earthquake hit California, killing 67 people, with £7bn of damage in the 1989 Loma Prieta earthquake; Chen Li De of China; China predicted earthquakes by radon gas; Huang Xiang Ning, who predicted an earthquake near Tangshan in late July 1976 - the 1976 Tangshan earthquake occurred on 28 July 1976; the Great Hanshin earthquake on 17 January 1995 in Japan, the worst for seventy years in Japan; nuclear physicist Motoji Ikeya of the University of Osaka; geophysicist Joseph Kirschvink of Caltech, who had worked with bees and electromagnetic fields. Narrated by Barbara Flynn, produced by Bill Jones, directed by Chris Malone, made by Granada Television with the Discovery Channel 17 May Deadly Code, about biological weapons and genetic engineering; Vivienne Nathanson of the BMA; ethnic bioweapons; a religious cult leaves nerve gas on Tokyo underground trains in January 1995; Richard A.
=== Cancer treatment === Pardaxin inhibits proliferation and induces apoptosis of human cancer cell lines. Its 33-amino acid structure contains many cationic and amphipathic amino acids. This makes it easier for it to interact with anionic membranes, such as those in tumor cells, which are inherently more acidic because of the acidic environment created by more glycolysis. Pardaxin initiates caspase-dependent and caspase-independent apoptosis in human cervical carcinoma cells. Pardaxin triggers reactive oxygen species (ROS). ROS production disrupts protein folding and induces the unfolded protein response (UPR). This causes stress on the endoplasmic reticulum, which releases calcium. This leads to an increase in mitochondrial calcium, dropping its membrane potential. The pore permeability changes, and Cytochrome c (Cyt c) is released. Cyt c activates the caspase chain that leads to apoptosis. ROS also activates the JNK pathway. JNK is phosphorylated, which leads to the phosphorylation of AP-1 (transcription factor consisting of cFOS and Cjun). This results in the activation of caspases as well. ROS also causes a caspase independent pathway that results in apoptosis. When the mitochondrial membrane potential changes, apoptosis-inducing factors (AIFs) are also released. These trigger apoptosis when they enter the nucleus, not needing to involve caspases.
Sources: en.wikipedia.org
Nicotinamide mononucleotide ("NMN" and "β-NMN") is a nucleotide derived from ribose, nicotinamide, nicotinamide riboside and niacin. In humans, several enzymes use NMN to generate nicotinamide adenine dinucleotide (NADH). In mice, it has been proposed that NMN is absorbed via the small intestine within 10 minutes of oral uptake and converted to nicotinamide adenine dinucleotide (NAD+ form) through the Slc12a8 transporter. However, this observation has been challenged, and the matter remains unsettled. Because NADH is a cofactor for processes inside mitochondria, for sirtuins and PARP, NMN has been studied in animal models as a potential neuroprotective and anti-aging agent. The alleged anti-aging effect at the cellular level by inhibiting mitochondrial decay in presence of increased levels of NAD+ makes it popular among anti-aging products. Dietary supplement companies have aggressively marketed NMN products, claiming those benefits. However, no human studies to date have properly proven its anti-aging effects with proposed health benefits only suggested through research done in vitro or through animal models. Single-dose administration of up to 500 mg was shown safe in men in a study at Keio University. One 2021 clinical trial found that NMN improved muscular insulin sensitivity in prediabetic women, while another found that it improved aerobic capacity in amateur runners. A 2023 clinical trial showed that NMN improves performance on a six-minute walking test and a subjective general health assessment.
== Publications == Pratley, Richard E; Nauck, Michael; Bailey, Timothy; Montanya, Eduard; Cuddihy, Robert; Filetti, Sebastiano; Thomsen, Anne Bloch; Søndergaard, Rie Elvang; Davies, Melanie (2010). "Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial". The Lancet. 375 (9724): 1447–56. doi:10.1016/S0140-6736(10)60307-8. PMID 20417856. S2CID 3291387. Buse, John B; Rosenstock, Julio; Sesti, Giorgio; Schmidt, Wolfgang E; Montanya, Eduard; Brett, Jason H; Zychma, Marcin; Blonde, Lawrence (2009). "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)". The Lancet. 374 (9683): 39–47. doi:10.1016/S0140-6736(09)60659-0. PMID 19515413. S2CID 25135640. Jensterle, M.; Sebestjen, M.; Janez, A.; Prezelj, J.; Kocjan, T.; Keber, I.; Pfeifer, M. (2008). "Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome". European Journal of Endocrinology. 159 (4): 399–406. doi:10.1530/EJE-08-0507. PMID 18653546. Jensterle, M; Weber, M; Pfeifer, M; Prezelj, J; Pfutzner, A; Janez, A (2008). "Assessment of insulin resistance in young women with polycystic ovary syndrome". International Journal of Gynecology & Obstetrics. 102 (2): 137–40. doi:10.1016/j.ijgo.2008.03.017. PMID 18504045. S2CID 13513083. Jensterle, M.; Janez, A.; Mlinar, B.; Marc, J.; Prezelj, J.; Pfeifer, M. (2008).
The transformation of the Jardin ('Garden') from the medicinal garden of the king to a national public museum of natural history required the creation of twelve chaired positions. Over the ensuing years the number of Chairs and their subject areas evolved, some being subdivided into two positions and others removed. The list of Chairs of the MNHN includes major figures in the history of the Natural sciences. Early chaired positions were held by Jean-Baptiste Lamarck, René Desfontaines, and Georges Cuvier, and later occupied by Paul Rivet, Léon Vaillant, and others.
During its fourth year, Gearbox began working on its first independently owned game: Brothers in Arms: Road to Hill 30. Developed for PC and Microsoft's Xbox console, and built with the Unreal Engine 2, it was released in March 2005. The sequel, Brothers in Arms: Earned in Blood, followed seven months later. The series was published by Ubisoft, who supported both games with PlayStation 2 versions, and later worked with it to develop Brothers in Arms games for portable systems (mobile phones, PlayStation Portable and Nintendo DS) and the Wii home console. In 2005, Gearbox licensed the Unreal Engine 3 from Epic Games, to replace the Unreal Engine 2 technology used in previous games, and grew its internal development teams to handle the demands of next-generation technology and content. Brothers in Arms: Hell's Highway was the first new title to be announced, continuing the company's flagship franchise. Brothers in Arms: Hell's Highway was launched in September 2008. By 2008, the franchise also spun off a comic book series, a two-part television documentary, a line of action figures, and a novelization and non-fiction history book.
Born: Vyacheslav Gryaznov, Russian classical pianist; in Yuzhno-Sakhalinsk, Sakhalin, Russian SFSR, Soviet Union Filip Karadordević, U.S.-born Serbian businessman and heir to the throne of the abolished monarchy of Serbia and Yugoslavia as the eldest son of the former Crown Prince Alexander Karadordević, who was the only child of King Peter II of Yugoslavia; in Vienna, Virginia Died: Red Smith, 76, American sportswriter and columnist, died four days after he had published a column, which he headlined "Writing Less— and Better?" where he announced that he would be writing only three columns per week rather than four.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.